slc25a42 Antibody

What is SLC25A42 and why is it important for mitochondrial function?

SLC25A42 (solute carrier family 25 member 42) is a mitochondrial membrane protein that functions as the main transporter of coenzyme A (CoA) into mitochondria . This 318 amino acid protein with a molecular weight of approximately 35.4 kDa belongs to the mitochondrial carrier (TC 2.A.29) protein family . The protein plays a critical role in maintaining separate CoA pools between mitochondria and cytosol, which is essential for proper cellular metabolism . SLC25A42 has been proposed to import cytosolic CoA or dephospho-CoA (dPCoA) into mitochondria in exchange for 3'-phosphoadenosine 5'-phosphate (PAP) or adenine nucleotides . The importance of this transporter is underscored by the fact that mutations in the SLC25A42 gene cause mitochondrial encephalomyopathy characterized by myopathy, developmental delay, lactic acidosis, and other neurological manifestations .

What tissues express SLC25A42 and where is the protein localized?

SLC25A42 is widely expressed across many tissue types in humans . Its subcellular localization is specifically in the inner mitochondrial membrane, consistent with its function as a mitochondrial carrier protein . Expression data indicates that SLC25A42 shows varying levels of expression across different tissues, with notably lower expression in fibroblasts compared to other tissues . This expression pattern is important to consider when designing experiments using different cell types, as detection sensitivity may vary accordingly.

What applications are SLC25A42 antibodies commonly used for?

SLC25A42 antibodies are utilized in several key immunodetection applications:

• Immunocytochemistry (ICC) - The most common application for SLC25A42 antibodies

• Western Blot (WB) - For protein expression analysis

• Immunofluorescence (IF) - For cellular localization studies

• Immunohistochemistry (IHC) - For tissue distribution analysis

• Enzyme-Linked Immunosorbent Assay (ELISA) - For quantitative detection

The choice of application depends on the specific research question being addressed, with different antibody products optimized for particular techniques .

How can I distinguish between different splice variants of SLC25A42 using antibodies?

Distinguishing between SLC25A42 splice variants requires careful selection of antibodies targeting specific protein regions. Research has identified multiple splice variants, including variants missing 89 bp or 46 bp of exon 5, and variants retaining intron 5-6 . These alternative splice variants potentially encode proteins with reduced molecular weights (approximately 19.6 kDa, 14.6 kDa, and 17.6 kDa, respectively) compared to the reference 35.4 kDa protein, sharing only the N-terminus region .

For effective detection of these variants:

• Use antibodies directed against different regions (N-terminus, C-terminus, or whole sequence) to verify the presence of alternative protein products

• Consider the epitope locations carefully when selecting antibodies

• Perform Western blot analysis with appropriate molecular weight markers to identify the different size variants

• Be aware that detection sensitivity may be limited in tissues with low SLC25A42 expression, as evidenced by challenges in detecting the protein in fibroblast extracts

It's important to note that previous research attempts using multiple antibodies directed against different regions of SLC25A42 have encountered difficulties in detecting both canonical and alternative forms in fibroblasts, likely due to low expression levels in this cell type .

How do pathogenic mutations in SLC25A42 affect antibody binding and experimental outcomes?

Pathogenic mutations in SLC25A42, such as the missense variant c.871A>G (p.Asn291Asp) and the splice site variant c.380+2T>A, can significantly impact antibody recognition and experimental outcomes . These mutations may affect:

• Epitope accessibility: Conformational changes resulting from missense mutations can alter the three-dimensional structure of the protein, potentially masking or exposing different epitopes

• Protein expression levels: Mutations may lead to decreased protein stability, affecting detection sensitivity

• Alternative splicing: Splice site mutations, like c.380+2T>A, generate truncated proteins or alternative splice variants that may not be recognized by antibodies targeting the full-length protein

• Subcellular localization: Mutations may disrupt mitochondrial targeting, potentially altering the cellular distribution pattern observed in immunolocalization studies

When studying disease-associated variants, it's advisable to:

• Use multiple antibodies targeting different regions of the protein

• Compare antibody performance in wildtype versus mutant samples

• Consider complementary approaches (e.g., tagged overexpression constructs) for challenging cases

• Be aware that CoA content may be reduced by approximately 20% in cells with SLC25A42 loss-of-function mutations, which could affect metabolic studies

What are the cross-species reactivity considerations when using SLC25A42 antibodies?

When selecting SLC25A42 antibodies for studies involving different species, researchers should consider the evolutionary conservation and species-specific differences of this protein. SLC25A42 orthologs have been reported in mouse, rat, bovine, frog, zebrafish, chimpanzee, and chicken species . Available antibody products exhibit different cross-reactivity profiles:

When working with animal models, consider that:

• Functional studies in zebrafish have shown that knockdown of SLC25A42 causes morphological anomalies and motor defects, which can be rescued by human wildtype SLC25A42 mRNA but not disease-variant mRNA

• The degree of conservation in epitope regions will affect antibody performance across species

• Validation in each species of interest is strongly recommended before conducting extensive studies

What are the optimal sample preparation methods for detecting SLC25A42 in mitochondria?

Detecting SLC25A42 in mitochondria requires careful sample preparation due to its localization in the inner mitochondrial membrane and variable expression levels across tissues. Based on research findings, the following protocol is recommended:

• Mitochondrial isolation:

  • Use differential centrifugation techniques optimized for mitochondrial extraction

  • Consider density gradient purification for higher purity mitochondrial fractions

  • Maintain sample integrity by using protease inhibitors and keeping samples cold

• Membrane protein extraction:

  • Use appropriate detergents (e.g., digitonin, Triton X-100, or n-dodecyl β-D-maltoside) for solubilization

  • Optimize detergent concentration to extract membrane proteins without denaturing

  • Consider using specialized mitochondrial membrane protein extraction kits

• For Western blotting:

  • The observed molecular weight of SLC25A42 is approximately 33-35 kDa

  • Use freshly prepared samples, as freeze-thaw cycles may affect membrane protein integrity

  • Include positive controls known to express SLC25A42 (K-56 cells have been validated for detection)

• For immunocytochemistry/immunofluorescence:

  • Use mitochondrial markers (e.g., MitoTracker, TOMM20) for co-localization studies

  • Optimize permeabilization conditions to ensure antibody access to inner mitochondrial membranes

  • Consider confocal microscopy for precise subcellular localization

Note that detection sensitivity varies by tissue type, with fibroblasts showing particularly low expression levels that may challenge detection even with validated antibodies .

How can I validate the specificity of SLC25A42 antibodies in my experimental system?

Validating antibody specificity is crucial for reliable research results, especially for mitochondrial membrane proteins like SLC25A42. A comprehensive validation approach should include:

• Positive and negative controls:

  • Use tissues/cells with known high expression (based on transcriptomic data)

  • Include knockout/knockdown models or CRISPR-edited cell lines as negative controls

  • Compare multiple antibodies targeting different epitopes of SLC25A42

• Specificity validation techniques:

  • Perform peptide competition assays with the immunogen

  • Use orthogonal methods (e.g., mass spectrometry) to confirm target identity

  • Check for cross-reactivity with other mitochondrial carrier family members

• Application-specific considerations:

  • For Western blot: Confirm the observed band matches the expected molecular weight (33-35 kDa)

  • For immunocytochemistry: Demonstrate co-localization with established mitochondrial markers

  • For immunoprecipitation: Verify pulled-down protein by mass spectrometry

• Assessment of background and non-specific binding:

  • Test antibodies in tissues with low or no expression

  • Evaluate secondary antibody-only controls

  • Consider the use of isotype controls for monoclonal antibodies

Previous studies have encountered challenges in detecting SLC25A42 in fibroblasts using multiple antibodies directed against different protein regions, highlighting the importance of thorough validation in each experimental system .

What methods can be used to study SLC25A42 function in relation to coenzyme A transport?

Investigating SLC25A42's role in coenzyme A transport requires specialized methods that can assess both protein function and metabolic consequences. Based on research findings, the following approaches are recommended:

• Coenzyme A measurement:

  • Quantify total cellular CoA using enzymatic assays or mass spectrometry

  • Compare wildtype and SLC25A42-deficient models (a 20% reduction in CoA has been observed in patient fibroblasts)

  • Distinguish between mitochondrial and cytosolic CoA pools using subcellular fractionation

• Transport assays:

  • Reconstitute purified SLC25A42 in liposomes for in vitro transport studies

  • Measure CoA or dPCoA uptake in isolated mitochondria

  • Use radiolabeled or fluorescently tagged CoA derivatives to track transport

• Metabolic function analysis:

  • Measure activities of CoA-dependent enzymes in mitochondria

  • Assess metabolic pathways requiring mitochondrial CoA (e.g., TCA cycle, fatty acid oxidation)

  • Perform metabolomic profiling to identify altered metabolites

• Functional complementation studies:

  • Express wildtype SLC25A42 in patient-derived cells to rescue phenotypes

  • Use zebrafish or other model systems for in vivo functional studies (knockdown of SLC25A42 in zebrafish has been shown to cause morphological anomalies and motor defects)

  • Compare the effects of known pathogenic variants (e.g., c.871A>G, p.Asn291Asp) versus wildtype protein

These methodologies can be combined with antibody-based approaches (for protein localization and expression) to provide a comprehensive analysis of SLC25A42 function in normal physiology and disease states.

How are SLC25A42 antibodies used to investigate mitochondrial encephalomyopathy?

SLC25A42 antibodies serve as valuable tools for investigating the molecular basis of SLC25A42-associated mitochondrial encephalomyopathy, a disorder characterized by myopathy, developmental delay, lactic acidosis, and encephalopathy . Researchers can apply these antibodies in several key investigative approaches:

• Diagnostic applications:

  • Assess SLC25A42 protein expression in patient-derived tissues

  • Detect aberrant protein products resulting from pathogenic variants

  • Evaluate protein localization in affected tissues

• Pathophysiological investigations:

  • Study the impact of SLC25A42 mutations on protein expression and stability

  • Analyze mitochondrial morphology and distribution in patient samples

  • Correlate SLC25A42 expression with disease severity and clinical manifestations

• Functional studies:

  • Compare wildtype and mutant protein function in cellular models

  • Assess the impact of therapeutic interventions on protein expression

  • Investigate potential compensatory mechanisms in disease states

The severity of clinical manifestations in SLC25A42-associated mitochondrial encephalomyopathy is highly variable, ranging from asymptomatic lactic acidosis to severe intellectual disability, metabolic crisis, and multiorgan involvement . This clinical heterogeneity highlights the importance of comprehensive protein analysis using antibodies in understanding genotype-phenotype correlations.

What considerations should be made when using SLC25A42 antibodies in tissues from patients with different pathogenic variants?

When studying tissues from patients with different SLC25A42 pathogenic variants, researchers should consider several factors that may affect antibody performance and result interpretation:

• Variant-specific effects on protein expression:

  • Missense mutations (e.g., c.871A>G, p.Asn291Asp) may yield full-length protein with altered conformation

  • Splice site mutations (e.g., c.380+2T>A) can generate truncated proteins or alternative splice variants with different molecular weights (14.6-19.6 kDa)

  • Complete loss-of-function mutations may result in no detectable protein

• Epitope availability in different variants:

  • Select antibodies whose epitopes are not affected by the specific mutation

  • Consider using multiple antibodies targeting different regions (N-terminus, C-terminus, whole protein)

  • Be aware that conformational changes may affect epitope accessibility even if the sequence is unchanged

• Background genetic factors:

  • Control for ethnic background (the c.871A>G founder mutation is common in individuals of Arab descent)

  • Consider potential genetic modifiers that may influence protein expression

  • Compare related individuals with the same mutation but different clinical presentations

• Technical adjustments:

  • Optimize protein extraction methods for specific tissues

  • Adjust detection methods based on expected protein levels

  • Use appropriate controls (healthy tissues matched for age, sex, and ethnicity)

These considerations are particularly important given the reported challenges in detecting SLC25A42 even in control fibroblasts, suggesting that tissue-specific optimization is essential for successful antibody-based studies .

What future directions are emerging for SLC25A42 antibody applications in research?

The continued development and application of SLC25A42 antibodies promises to advance several emerging research areas:

• Expanded understanding of mitochondrial CoA metabolism:

  • Investigating the interplay between SLC25A42 and other CoA-related proteins like coenzyme A synthase (COASY)

  • Exploring the regulation of mitochondrial and cytosolic CoA pools

  • Characterizing the dynamics of CoA transport under different metabolic conditions

• Novel therapeutic approaches for SLC25A42-associated disorders:

  • Screening potential compounds that might modulate SLC25A42 function

  • Monitoring protein expression changes in response to therapeutic interventions

  • Developing biomarkers for disease progression and treatment response

• Broader implications for mitochondrial disease research:

  • Comparing SLC25A42-related phenotypes with other mitochondrial carrier defects

  • Investigating the role of SLC25A42 in more common neurological disorders

  • Exploring potential connections to aging and metabolic diseases

• Technical advancements:

  • Development of more sensitive antibodies for detecting low-abundance variants

  • Creation of phospho-specific antibodies to study post-translational regulation

  • Application of super-resolution microscopy techniques for detailed localization studies